Nobilis Health Corp. announced unaudited consolidated financial results for the first quarter ended March 31, 2017. For the quarter, the company reported total revenue of $68.302 million against $51.273 million a year ago. First quarter revenues were 33.2% higher than in the first quarter of 2016, driven by Medical Segment revenues, which comprised 95% of total revenue and were up 40% year-over-year. Contracted marketing revenues declined by approximately 60.4% as the company continued to shift case volumes to Nobilis facilities. Case volume increased 11.5% to 4,431 cases, and revenue per case increased year-over-year by 19.5% to $15,415 per case. This increase in revenue per case is primarily the result of the growth of the company's Hospital and Ancillary divisions. The increase in total revenue and total case volume in the first quarter of 2017 compared to the same quarter last year was primarily due to organic growth. Loss from operations was $3.135 million against $9.694 million a year ago. Loss before income taxes and non-controlling interests was $3.757 million against $8.682 million a year ago. Net loss attributable to company was $2.398 million or $0.03 per basic and fully diluted common share against $4.965 million or $0.07 per basic and fully diluted common share a year ago. Net cash provided by operating activities was $16.532 million against $4.462 million a year ago. Net cash provided by operating activities rose $12 million year-over-year for the first quarter of 2017. This was primarily the result of the year-over-year improvement in the operating results and the 17.8% or $22.2 million reduction in accounts receivable. Purchase of property and equipment was $3.506 million against $1.525 million a year ago. LBITDA was $0.273 million against $3.616 million a year ago. Adjusted EBITDA was $2.013 million against $0.351 million a year ago.

The company reiterated earnings guidance for the full year 2017. For the year, the company expects revenue in the range of $310.0 million to $325.0 million and adjusted EBITDA in the range of $40.0 million to $45.0 million.